FDA’s Meeting on Promotion – Can We Glimpse the Future?

In November, the FDA held a two-day Town Hall meeting to allow for input from stakeholders and patients surrounding agency regulation of manufacturer communications regarding unapproved uses of drugs and medical devices. This article provides a brief summary of the two-day event, including several presenters and their opinions.

It is no secret that ever since the Coronia case, the United States Food and Drug Administration (“FDA”) has been working on a comprehensive review of the regulatory framework related to firms’ communications about unapproved uses of approved/cleared medical products. These are products that are approved to be marketed for a particular use, but physicians and healthcare professionals have discovered other uses for the product that the FDA has not approved (e.g., unapproved use). The question dogging the FDA is whether a manufacturer may legally discuss the unapproved use with healthcare professionals beyond merely responding to a question if the information being imparted is both truthful and not misleading.

Read the full article in the February 2017 issue of Life Science Compliance Update

To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In
NEW
Comments (0)
Add Comment